Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients.Lewis JP, Backman JD, Reny JL, Bergmeijer TO, Mitchell BD, Ritchie MD, Déry JP, Pakyz RE, Gong L, Ryan K, Kim EY, Aradi D, Fernandez-Cadenas I, Lee MTM, Whaley RM, Montaner J, Gensini GF, Cleator JH, Chang K, Holmvang L, Hochholzer W, Roden DM, Winter S, Altman RB, Alexopoulos D, Kim HS, Gawaz M, Bliden KP, Valgimigli M, Marcucci R, Campo G, Schaeffeler E, Dridi NP, Wen MS, Shin JG, Fontana P, Giusti B, Geisler T, Kubo M, Trenk D, Siller-Matula JM, Ten Berg JM, Gurbel PA, Schwab M, Klein TE, Shuldiner AR, ICPC Investigators
(2020)
Eur Heart J Cardiovasc Pharmacother 6: 203-210
MeSH Terms: Aged, Brain Ischemia, Clopidogrel, Coronary Artery Disease, Coronary Thrombosis, Decision Support Techniques, Europe, Female, Humans, Male, Middle Aged, Myocardial Infarction, Percutaneous Coronary Intervention, Pharmacogenomic Variants, Platelet Aggregation, Platelet Aggregation Inhibitors, Polymorphism, Single Nucleotide, Predictive Value of Tests, Risk Assessment, Risk Factors, Stents, Stroke, Treatment OutcomeAdded March 24, 2020